Goserelin
GnRH agonist; Antigonadotropin | |
ATC code | |
---|---|
Legal status | |
Legal status | |
Pharmacokinetic data | |
Protein binding | 27.3% |
Elimination half-life | 4–5 hours |
Identifiers | |
| |
JSmol) | |
| |
| |
![]() ![]() |
Goserelin, sold under the brand name Zoladex among others, is a
Structurally, it is a
Goserelin stimulates the production of the sex hormones testosterone and estrogen in a non-pulsatile (non-physiological) manner. This causes the disruption of the endogenous hormonal feedback systems, resulting in the down-regulation of testosterone and estrogen production.
It was patented in 1976 and approved for medical use in 1987.[4] It is on the World Health Organization's List of Essential Medicines.[5]
Medical uses
Goserelin is used to treat hormone-sensitive cancers of the
Side effects
Goserelin may cause
Short-term memory impairment has also been reported in women and may in some cases be severe, but this effect disappears gradually once treatment is discontinued.[8]<[9]
Pharmacology
Goserelin is a synthetic analogue of a naturally occurring
Chemistry
Goserelin is a
.Society and culture
Names
Goserelin is the
, .References
- ^ "Product monograph brand safety updates". Health Canada. 6 June 2024. Retrieved 8 June 2024.
- ISBN 978-0-412-54090-5.
- ISBN 978-94-011-4439-1.
- ISBN 9783527607495.
- hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
- PMID 16320157.
- PMID 16321765.
- ^ Newton CR, Yuzpe AA, Timmon IS, Slota MD (October 1993). Memory complaints: a side effect of continued exposure to gonadotropin-releasing hormone agonists (GnRHa). Conjoint Annual Meetings of the American Fertility Society and the Canadian Fertility and Andrology Society. Montreal, Canada.
- PMID 8425646.
- PMID 10678560.